Press Releases

Dominari Holdings Inc. today provided an update on the $2 million share repurchase program authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on March 3, 2023, the Company purchased 4000 shares of common stock at $­­­­­­­4.4086 per share. Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of

BioTouch™, a leading provider of outsourced medical supplies, kitting, and logistics services to the healthcare industry and portfolio company of Atlantic Street Capital, announced today that it has acquired Titan Solutions, a leading provider of logistics, kitting, and life sciences supply chain management solutions based in Shannon, Ireland. This acquisition will significantly expand the international capabilities of BioTouch and enhance its position as a global leader in healthcare s

ClinChoice Medical Development is pleased to announce the acquisition of CROMSOURCE Srl, an ISO-certified full-service contract research organization headquartered in Verona , Italy and its US headquarters in Cary, North Carolina . CROMSOURCE has offices in the United States and in seven countries in Western and Eastern Europe, as well as field representatives in various locations in Europe and the United States . Founded in 1997, CROMSOURCE has a proven track record of supporting g

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives. Alongside their CSO & co-founder (B.PINTEUR) and CEO (P.BRAVETTI) this committee reinforces a solid expertise in health tech & pharma industry manufacturing to support the strategic development of the company and anti

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on significant progress made in the field of cannabis research. MediPharm remains focused on investing in clinical research and supporting the development of future cannabis derived pharmaceutical drugs. Consistent with this commitment, the Company will supply the Spons

WISeKey International Holding Ltd a cybersecurity IoT platform company, today announced that it has develop a new IoT anti-counterfeiting TAG based on its U.S. patent. Pub No. US2019/0114522 A1 https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20190114522 The TAG is designed and strategically placed inside the pharmaceutical package including bottles and containers used to package and ship medications. When the device is intact, it can be interrogated remotely by an N

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension." This issued patent further strengthens the Company's intellectual property position and coverage for the Company's approved therapeutic

Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Infinity Pharmaceuticals, Inc. relating to its proposed merger with MEI Pharma, Inc.. Under the terms of the agreement, INFI shareholders are expected to own approximately 42% of the newly combined company. Clic

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE-718 is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction. Multiple clinical studies are ongoing with SAGE-718 across several disease areas, including two placebo-controll

Impel Pharmaceuticals, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it will implement an operational streamlining plan that will include a reduction of employee and non-employee expenses, largely impacting the research and development functions of the organization. The Company plans to reprioritize spend to capitalize on the continued positive momentum in payor and prescribe